Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Comprehensive Overview of SciSparc Ltd (SPRC)
SciSparc Ltd is a specialty clinical‐stage pharmaceutical company that leverages cutting‐edge cannabinoid technologies to develop innovative immunotherapy products and address central nervous system disorders. At its core, SciSparc focuses on the development of therapies derived from cannabinoid molecules, incorporating advanced biotechnology, immunotherapy, and clinical research methodologies. This dual‐focused enterprise operates across two distinct segments: one dedicated to clinical drug development and regulatory pathways, and another which drives the online sale of hemp-based consumable products.
Clinical-Stage Drug Development
The company’s primary business revolves around its clinical-stage drug development programs. SciSparc employs a portfolio based on both THC and non-psychoactive CBD compounds to create novel treatments for disorders such as Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus. Utilizing a rigorous, research-driven approach, the company undertakes controlled clinical trials designed to evaluate drug efficacy, safety, and tolerability. With its IND applications and approvals for advanced clinical programs, SciSparc demonstrates its commitment to meeting stringent regulatory standards and addressing unmet medical needs in its target therapeutic areas.
Innovative Technology and Intellectual Property
SciSparc’s market positioning is strengthened by its robust portfolio of patents and proprietary technologies. The company’s innovations in cannabinoid pharmaceuticals are not only geared towards improving treatment outcomes but also distinguishing its offerings from traditional therapies. By investing in advanced research platforms, including computational drug discovery and predictive artificial intelligence models, SciSparc is able to screen and identify promising molecular candidates for further development. This technological prowess, combined with a clear focus on regulatory compliance and scientific excellence, forms the backbone of its strategic differentiation.
Online Sales and Hemp-Based Consumer Products
In addition to its core clinical operations, SciSparc diversifies its business model through a reportable segment that manages the online sale of a wide range of hemp-derived products. These products, which include hemp gummies, oil capsules, topical gels, creams for beauty and hair treatments, and other nutraceutical items, are manufactured domestically in the United States. This segment not only leverages SciSparc’s expertise in cannabinoid science but also capitalizes on the growing consumer demand for hemp-based nutritional and wellness products.
Strategic Positioning in a Competitive Landscape
SciSparc operates in a competitive and dynamic landscape where rigorous clinical research, robust intellectual property protection, and diversified revenue streams are critical. The company’s dual approach—pursuing breakthrough therapies through detailed clinical trials while also serving a broad consumer market with hemp-based products—allows it to mitigate risk and explore multiple avenues for value creation. By maintaining adherence to high standards of scientific inquiry and regulatory diligence, SciSparc reinforces its position as a trusted and innovative entity within the pharmaceutical and nutraceutical industries.
Expertise, Experience, and Trustworthiness
The expertise demonstrated by SciSparc’s team of senior executives and scientists adds a further layer of credibility to its endeavors. The company’s rigorous research protocols, combined with its strategic investments in cutting-edge technology and regulatory expertise, underscore its commitment to scientific excellence and long-term value creation. This methodical, research-intensive approach not only builds trust among stakeholders but also serves as a foundation for advancing next-generation therapies in areas that have long presented clinical challenges.
Conclusion
In summary, SciSparc Ltd exemplifies a forward-thinking pharmaceutical enterprise that effectively blends innovative drug development with consumer-oriented online sales. Its robust portfolio in cannabinoid-based immunotherapies, supported by extensive intellectual property and strategic clinical trials, positions it uniquely within a competitive market landscape. Whether addressing central nervous system disorders or fulfilling the growing consumer demand for hemp products, SciSparc’s dual business model represents a comprehensive and balanced approach to modern pharmaceutical innovation.
SciSparc announced that shareholders approved all proposals at their adjourned annual general meeting held on June 26, 2025. The meeting resulted in the approval of two significant documents:
- A new amended and restated articles of association
- An updated compensation policy for executive officers and directors
These approvals were obtained with the requisite majority in accordance with Israeli Companies Law and the company's existing articles of association. The proposals were previously detailed in a proxy statement furnished to the SEC on May 21, 2025.
The Form 6-K filing will be incorporated into multiple company registration statements, including several Form F-3s (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408) and Form S-8s (File Nos. 333-278437, 333-225773, 333-286791). The document was signed by Oz Adler, Chief Executive Officer.
SciSparc has filed an amended F-4 registration statement regarding its proposed merger with AutoMax Motors. The merger agreement, initially signed on April 10, 2024, and amended multiple times through May 8, 2025, will result in AutoMax becoming a wholly-owned subsidiary of SciSparc.
Key terms of the merger include:
- AutoMax shareholders and advisor will own approximately 49.99% of SciSparc's share capital post-merger
- SciSparc shareholders will retain approximately 50.01% ownership
- SciSparc will maintain its Nasdaq listing under symbol "SPRC"
- Expected closing in Q3 2025, subject to shareholder and court approvals
A special shareholder meeting is scheduled for August 13, 2025 to vote on: merger approval, new indemnification agreements for directors/officers, executive bonuses contingent on merger closing, and election of new board members. Post-merger, Oz Adler will serve as CEO/CFO, with Dr. Adi Zuloff-Shani as CTO.
SciSparc announced the adjournment of its Annual General Meeting of Shareholders due to lack of quorum on June 25, 2025. The Adjourned Annual Meeting is rescheduled for June 26, 2025, at 8:00 a.m. (Eastern Time) / 3:00 p.m. (Israel time) at the company's Tel Aviv offices.
Key details:
- If quorum is not achieved within 30 minutes of the rescheduled meeting, any number of shareholders present in person, by proxy, or who delivered a proxy card will constitute a quorum
- Previously submitted proxy cards for the original meeting will remain valid for the Adjourned Meeting
- The Form 6-K will be incorporated into multiple registration statements, including Form F-3 and Form S-8 filings
The report was signed by Oz Adler, Chief Executive Officer, on June 25, 2025.
SciSparc Ltd has announced a significant corporate action with a 1-for-21 reverse share split as reported in their Form 6-K filing dated June 28, 2025. This strategic move will consolidate every 21 existing shares into 1 new share.
Key filing details:
- Filing incorporates by reference into multiple registration statements, including Form F-3 (6 filings) and Form S-8 (3 filings)
- Document signed by Oz Adler, who serves as both Chief Executive Officer and Chief Financial Officer
- Company maintains its principal executive offices in Tel Aviv, Israel
- Confirms status as a Form 20-F filer for annual reports
The reverse split announcement suggests a potential strategic effort to meet minimum share price requirements for continued exchange listing or improve the stock's marketability to institutional investors.
SciSparc (Nasdaq: SPRC) filed Amendment No. 2 to its Form F-3 shelf registration, allowing the resale of up to 61,209,538 ordinary shares by existing investors.
The shares consist of (i) 53,617,021 shares issuable upon conversion of $4.2 million in convertible debentures and (ii) 7,592,517 shares issuable upon exercise of warrants. The debenture conversion price equals the lower of a fixed $0.4681 or 95 % of the 20-day VWAP, with a $0.0846 floor; warrants are exercisable at $0.5532. SciSparc will receive no proceeds from share resales, but could receive up to roughly $4.2 million in cash should all warrants be exercised.
The filing reiterates the company’s strategy of developing cannabinoid-based therapeutics (programs SCI-110 and SCI-210) and summarizes its pending merger with AutoMax Motors, an Israeli vehicle importer. The Merger Agreement has been amended four times (latest on 8 May 2025) and remains subject to shareholder approval.
Key investor considerations include: potential dilution from a share count materially larger than current float, a resale overhang that could pressure the $0.321 market price, and ongoing uncertainty surrounding the AutoMax merger. Risk factors highlight limited U.S. enforceability of judgments against the Israeli company and management, and the clinical-stage nature of operations with IFRS-based financials.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
What is the primary focus of SciSparc Ltd?
How does SciSparc generate its revenue?
What types of disorders is SciSparc targeting?
How does SciSparc differentiate itself in the pharmaceutical industry?
What role do patents and proprietary technologies play at SciSparc?
How does SciSparc manage regulatory compliance?
What market segments does SciSparc serve?
How experienced is the management team at SciSparc?
